Rigel Pharmaceuticals (RIGL) Debt to Equity (2019 - 2025)
Rigel Pharmaceuticals has reported Debt to Equity over the past 7 years, most recently at $0.21 for Q4 2025.
- For Q4 2025, Debt to Equity fell 98.97% year-over-year to $0.21; the TTM value through Dec 2025 reached $0.21, down 98.97%, while the annual FY2025 figure was $0.21, 98.97% down from the prior year.
- Debt to Equity for Q4 2025 was $0.21 at Rigel Pharmaceuticals, down from $0.51 in the prior quarter.
- Over five years, Debt to Equity peaked at $20.36 in Q4 2024 and troughed at -$8.11 in Q2 2022.
- A 5-year average of $0.08 and a median of -$0.83 in 2023 define the central range for Debt to Equity.
- On a YoY basis, Debt to Equity climbed as much as 1632.37% in 2022 and fell as far as 2882.69% in 2022.
- Year by year, Debt to Equity stood at $0.66 in 2021, then crashed by 541.89% to -$2.9 in 2022, then grew by 28.18% to -$2.08 in 2023, then surged by 1078.6% to $20.36 in 2024, then plummeted by 98.97% to $0.21 in 2025.
- Business Quant data shows Debt to Equity for RIGL at $0.21 in Q4 2025, $0.51 in Q3 2025, and $0.73 in Q2 2025.